| MargheRITA (Remote Intelligence for Therapeutic Adherence) (NCT05260203) | Advice Pharma Group srl | 2022-06-04 |
| Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies (NCT04823091) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2021-04-15 |
| Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances (NCT04934774) | iCell Gene Therapeutics | 2020-12-01 |
| Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies (NCT05127135) | Fundamenta Therapeutics, Ltd. | 2020-01-22 |
| A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) (NCT03833180) | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2019-03-14 |
| Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma (NCT03590574) | Autolus Limited | 2018-08-30 |
| Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer (NCT03333486) | Roswell Park Cancer Institute | 2017-12-07 |
| Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies (NCT03263637) | AstraZeneca | 2017-10-24 |
| Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia (NCT03195010) | Fred Hutchinson Cancer Center | 2017-06-09 |
| Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma (NCT03061188) | Northwestern University | 2017-05-23 |
| Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas (NCT02859402) | Keimyung University Dongsan Medical Center | 2016-12-01 |
| CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma (NCT02424968) | Robert Lowsky | 2015-06-01 |
| Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies (NCT01919619) | M.D. Anderson Cancer Center | 2013-11-04 |
| A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma (NCT01908777) | Memorial Sloan Kettering Cancer Center | 2013-07-16 |
| CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma (NCT01746173) | Dana-Farber Cancer Institute | 2013-07-01 |
| Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma (NCT00992446) | Fred Hutchinson Cancer Center | 2010-09-02 |
| Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant (NCT00880815) | M.D. Anderson Cancer Center | 2009-02-17 |
| Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer (NCT00723099) | Fred Hutchinson Cancer Center | 2008-06-25 |
| Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma (NCT00684411) | Dana-Farber Cancer Institute | 2008-06-01 |